PIN29 ESTIMATION OF THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A TEST AND TREAT (T&T) ANTIRETROVIRAL (ARV) REGIMEN FOR TREATMENT-NAIVE PATIENTS WITH HIV-1 INFECTION IN THE UNITED STATES
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI